Literature DB >> 35121869

Splitting signals drives CARs further.

Tiffany R King-Peoples1, Avery D Posey2,3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 35121869     DOI: 10.1038/s43018-021-00257-x

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


× No keyword cloud information.
  14 in total

1.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Authors:  Omkar U Kawalekar; Roddy S O'Connor; Joseph A Fraietta; Lili Guo; Shannon E McGettigan; Avery D Posey; Prachi R Patel; Sonia Guedan; John Scholler; Brian Keith; Nathaniel W Snyder; Nathaniel Snyder; Ian A Blair; Ian Blair; Michael C Milone; Carl H June
Journal:  Immunity       Date:  2016-02-16       Impact factor: 31.745

2.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Authors:  Eugenia Zah; Meng-Yin Lin; Anne Silva-Benedict; Michael C Jensen; Yvonne Y Chen
Journal:  Cancer Immunol Res       Date:  2016-04-08       Impact factor: 11.151

Review 3.  Metabolic regulation of T lymphocytes.

Authors:  Nancie J MacIver; Ryan D Michalek; Jeffrey C Rathmell
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

4.  CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Authors:  Andras Heczey; Chrystal U Louis; Barbara Savoldo; Olga Dakhova; April Durett; Bambi Grilley; Hao Liu; Mengfeng F Wu; Zhuyong Mei; Adrian Gee; Birju Mehta; Huimin Zhang; Nadia Mahmood; Haruko Tashiro; Helen E Heslop; Gianpietro Dotti; Cliona M Rooney; Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-06-09       Impact factor: 11.454

5.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

6.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

7.  Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development.

Authors:  David O'Sullivan; Gerritje J W van der Windt; Stanley Ching-Cheng Huang; Jonathan D Curtis; Chih-Hao Chang; Michael D Buck; Jing Qiu; Amber M Smith; Wing Y Lam; Lisa M DiPlato; Fong-Fu Hsu; Morris J Birnbaum; Edward J Pearce; Erika L Pearce
Journal:  Immunity       Date:  2014-07-04       Impact factor: 31.745

8.  Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

Authors:  Nirav N Shah; Bryon D Johnson; Dina Schneider; Fenlu Zhu; Aniko Szabo; Carolyn A Keever-Taylor; Winfried Krueger; Andrew A Worden; Michael J Kadan; Sharon Yim; Ashley Cunningham; Mehdi Hamadani; Timothy S Fenske; Boro Dropulić; Rimas Orentas; Parameswaran Hari
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

9.  Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.

Authors:  Judith Feucht; Jie Sun; Justin Eyquem; Yu-Jui Ho; Zeguo Zhao; Josef Leibold; Anton Dobrin; Annalisa Cabriolu; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Med       Date:  2018-12-17       Impact factor: 53.440

10.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.

Authors:  Christopher C Kloss; Maud Condomines; Marc Cartellieri; Michael Bachmann; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2012-12-16       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.